Interferon alpha

Links to news articles on Interferon alpha .

Swiss OK for Bayer/Onyx' Nexavar -- 30 Mar 2006
...on average, but it also appears to be much less toxic than current treatments for this type of cancer, such as interleukin-2 or interferon-alpha, and has the ... Pharma Times (subscription),

PowderMed's Therapeutic DNA Vaccine for Chronic Hepatitis B Enters ... -- Mar 29, 2006
...immune response to a broad range of viral and cancer antigens, that ... chronic hepatitis B infection is limited to immunomodulators (Interferon alpha (IFN-(alpha ... PharmaLive.com (press release),

International Award Honors Discoveries In Cellular And Molecular ... -- Mar 23, 2006
...at The Cancer Institute of Japanese Foundation of Cancer Research, after his ... of a cytokine: At the same time, the structure of interferon-alpha was elucidated ... Medical News Today (press release),

Helix BioPharma announces Q2 2006 financial results -- Mar 14, 2006
...for the Phase II clinical program of the Company's Topical Interferon Alpha-2b, research expenditures relating to the Company's novel anti-cancer therapeutic, L ... Canada NewsWire (press release),

Hepatitis C Treatment for People With Severe Mental Illness -- Feb 28, 2006
Capuron L, Ravaud A, Dantzer R: Timing and specificity of the cognitive changes induced by interleukin-s and interferon-alpha in cancer patients. ... Psychosomatics (subscription)

Sciclone’s Zadaxin Granted Orphan Drug Designation for Malignant ... -- Mar 20, 2006
...include chemotherapeutic agents, like dacarbazine (DTIC), and immunotherapeutics, including interferon alpha. ... site and the extent to which the cancer has spread ... PharmaLive.com (press release),

Helix Biopharma Announces Q2 2006 Financial Results -- Mar 15, 2006
...the Phase II clinical program of the Company’s Topical Interferon Alpha-2b, research expenditures relating to the Company’s novel anti-cancer therapeutic, L ... PharmaLive.com (press release),

FDA orphan status for SciClone skin cancer drug -- Mar 20, 2006
...the treatment of stage IIb through stage IV malignant melanoma, or skin cancer. ... dacarbazine (DTIC) chemotherapy with and without low-dose interferon alpha in a ... Pharmaceutical Business Review

Baylor Research Institute Receives $2.9 Million to Study Lupus -- Feb 28, 2006
Reducing the serum level of interferon alpha with an antibody could provide ... involve the immune system, such as autoimmune diseases, cancer, infectious diseases ... PharmaLive.com (press release),

MethylGene Announces Year-End 2005 Financial Results and Updates ... -- Mar 9, 2006
...proprietary demethylating agent, is near completion of the first step of the Phase II trial in combination with interferon alpha in renal cell cancer patients. ... CCNMatthews (press release),

Mesothelioma Treatment 101 -- Mar 2, 2006
...to the patient (while it may benefit patients with bladder cancer). ... Nonetheless, other trials involving interferon alpha have proved more encouraging with 20 ... Only Idol,

Medarex Announces 2005 Fourth Quarter and Year End Financial ... -- Mar 6, 2006
...or IND, for MEDI-545, a fully human antibody targeting interferon-alpha that is ... the advancement of BMS- 66513, a fully human antibody for cancer, into clinical ... Yahoo! News (press release)

Human Genome Sciences Reports on Progress Toward Commercialization ... -- Jan 10, 2006
...safety of Albuferon in combination with ribavirin in interferon alpha-naive patients ... as monotherapy in advanced non-small cell lung cancer, advanced colorectal ... MSN Money

Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in ... -- Jan 12, 2006
...death, liver decompensation, liver transplant or liver cancer (hepatocellular carcinoma). ... or equal to 1% with PEG-INTRON or interferon alpha: Severe decreases ... PR Newswire (press release),

ChemGenex Granted US Patent on Ceflatonin(R)'s Use for Treatment ... -- Jan 17, 2006
...with a range of drugs including cytarabine, interferon alpha, Gleevec, farnesyl ... The company has a significant portfolio of anti-cancer, diabetes, obesity and ... PR Newswire (press release),

Chronic Hepatitis C Treatment, Peg-Intron(R) And Rebetol(R) ... -- Dec 27, 2005
Hepatitis C is the leading cause in Japan of liver cancer, with more than ... liver disease who have not been previously treated with interferon alpha and who are ... Medical News Today (press release),

Advances in treatment of chronic myeloid leukaemia -- Jan 13, 2006
...are Imatinib-resistant or intolerant," said Charles Sawyers, Jonsson Cancer Center, UCLA ... Hydroxyurea or Anagrelide in 86 percent, and Interferon alpha in 70 ... Xagena.it,

AVI BioPharma Reports Favorable Safety and Pharmacokinetic Data ... -- Jan 10, 2006
...in the US from HCV-related cirrhosis or liver cancer. The current treatment for HCV, 24 to 48 weeks of therapy with pegylated interferon alpha and ribavirin ... Genetic Engineering News,

HGS Signs Amgen, PDL For Partners In Non-Core Assets -- Jan 10, 2006
...applications in autoimmune diseases, immune deficiencies or suppression and cancer. ... start Phase III development of Albuferon (albumin-interferon alpha 2b) for ... BioWorld Online (subscription),

Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior ... -- Jan 4, 2006
...of seasonal allergic rhinitis, (4) peg-intron(R) (pegilated interferon-alpha 2-b ... for the treatment of life-threatening diseases, including diabetes and cancer. ... PR Newswire (press release),

International Approvals: Erbitux, Peg-Intron, Rebetol -- Dec 27, 2005
...for the first-line treatment of locally advanced head and neck cancer. ... compensated liver disease and who have not previously received interferon alpha therapy. Medscape (subscription)

FDA Approvals: Nexavar and Tamiflu -- Dec 28, 2005
...conventional treatment with biologics such as interleukin-2 or interferon-alpha (median PFS ... additional phase 3 trial in non-small cell lung cancer is planned ... Medscape (subscription)

Helix BioPharma Corp. signs L-DOS47 Manufacturing Agreement with ... -- Dec 22, 2005
...prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and ... CNW Telbec (Communiqués de presse),

Helix BioPharma Corp. signs L-DOS47 Manufacturing Agreement with ... -- 23 Dec 2005
...prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and ... CNW Telbec (Communiqués de presse),

Schering-Plough Announces PEG-INTRON(R) and REBETOL(R) Approved in ... -- Dec 22, 2005
Hepatitis C is the leading cause in Japan of liver cancer, with more than ... liver disease who have not been previously treated with interferon alpha and who are ... PR Newswire (press release),

Helix Biopharma Announces Q1 2006 Financial Results -- Dec 20, 2005
...the Phase II clinical program of the Company’s Topical Interferon Alpha-2b, research expenditures relating to the Company’s novel anti-cancer therapeutic, L ... PharmaLive.com (press release),

Helix BioPharma announces Q1 2006 financial results -- Dec 15, 2005
...for the Phase II clinical program of the Company's Topical Interferon Alpha-2b, research expenditures relating to the Company's novel anti-cancer therapeutic, L ... CNW Telbec (Communiqués de presse),

SciClone Reports Results From First ZADAXIN Phase 3 Hepatitis C ... -- Dec 14, 2005
...are previous non-responders to the combination of pegylated interferon alpha plus ribavirin ... an important role in eradicating virally infected and cancer cells. ... Market Wire (press release)

SciClone and Sigma-Tau Report Promising Interim Phase 2 Results in ... -- Dec 14, 2005
IV, the most advanced form, once the cancer has spread ... IV patients include chemotherapeutic agents, like DTIC, and immunotherapy, including interferon alpha. ... Market Wire (press release)

Maxygen Announces Achievement of Milestone in Roche Alliance -- Dec 14, 2005
Analysts estimate that sales of interferon alpha products may reach approximately $5.8 ... and in many patients it leads to liver disease, cirrhosis and cancer. ... PharmaLive.com (press release),

Roche and Maxygen to Co-Develop Recombinant Factor VIIa ... -- Dec 15, 2005
Maxygen has developed a novel interferon alpha product that Roche is advancing into ... in diagnostics, the leading supplier of pharmaceuticals for cancer, as well ... PR Newswire (press release),

More Than 90% of Patients Taking Gleevec(R) for a Form of Chronic ... -- Dec 12, 2005
...stem cell transplantation or resistance to interferon-alpha therapy ... cardiovascular diseases, dermatological diseases, respiratory disorders, cancer and arthritis ... Yahoo! News (press release)

New Data Suggest Novel Low-dose Outpatient Chemobiotherapy Regimen ... -- Dec 12, 2005
...with LEUKINE at 125 mcg/m(2) to a maximum 250 mcg, Interferon-alpha-2b at ... More than one million new cases of skin cancer will be diagnosed in the United States ... PR Newswire (press release),

Glivec Seeking to Become First Targeted Treatment for Adult ... -- Dec 13, 2005
...drug design based on an understanding of how some cancer cells work. ... rise to differentiated cells) transplant or who are resistant to interferon-alpha treatment ... PharmaLive.com (press release),

New Studies Identify Advances In Treatment Of Chronic Myeloid ... -- Dec 13, 2005
...resistant or intolerant," said Charles Sawyers, MD, Jonsson Cancer Center, UCLA ... 100 percent hydroxyurea or anagrelide in 86 percent, and interferon alpha in 70 ... Science Daily (press release)

Partnership to develop new renal cancer test -- Dec 13, 2005
RCC is an aggressive cancer, with a lack of early warning signs ... and infrequent responses to immunotherapy agents such as interferon alpha and interleukin (IL)-2 ... OutSourcing-Pharma.com,

MethylGene Reports Encouraging Preliminary Clinical Results for ... -- Dec 8, 2005
MG98 has entered a randomized two-step Phase II combination trial with interferon alpha in metastatic renal cell cancer. MethylGene ... CCNMatthews (press release),

Ambrx and Roche Enter Into Broad Technology Collaboration -- Dec 7, 2005
...use the technology platform to generate novel pegylated interferon alpha molecules. ... in diagnostics, the leading supplier of pharmaceuticals for cancer, as well ... PR Newswire (press release),

Human Genome Sciences Announces Decision to Spin Off CoGenesys ... -- Dec 13, 2005
...albumin- interferon-alpha) for the treatment of chronic hepatitis C; and HGS-ETR1 (mapatumumab) for the treatment of non-small cell lung cancer, colorectal ... PR Newswire (press release),

The lowdown on thyroid slowdown -- Dec 11, 2005
...medication lithium; interferon alpha, which is used to treat hepatitis C and certain types of leukemia and other cancers; and the cancer drug interleukin-2 ... ITP.net,

Fatigue And Hypothyroidism -- Dec 6, 2005
...medication lithium; interferon alpha, which is used to treat hepatitis C and certain types of leukemia and other cancers; and the cancer drug interleukin-2. ... Hollister Free Lance,

Interferon-Alpha Reduces Liver Cancer Risk and Mortality in ... -- Nov 18, 2005
Previous data showed interferon-alpha reduces the risk of liver cancer in hepatitis C patients, especially those who achieved a sustained virological response ... DG News

Survival Unaffected by Interferon Alpha-2b after Surgical ... -- Nov 15, 2005
PhD, Associate Investigator and Attending Physician, National Cancer Research Center ... carcinoma were randomized to receive treatment with interferon alpha-2b or ... DG News

MethylGene Reports Interim Clinical Results for MGCD0103 -- Nov 15, 2005
MG98 has entered a randomized two-step Phase II combination trial with interferon alpha in metastatic renal cell cancer. MethylGene ... CCNMatthews (Communiqués de presse),

Pegasys (peginterferon alpha-2a) Shows Encouraging Interim Results ... -- Nov 11, 2005
...and is the leading cause of cirrhosis and liver cancer and the ... C who have compensated liver disease and have not previously been treated with interferon alpha. ... DG News

2nd Phase II Trial with Trovax® in Renal Cell Carcinoma, Oxford ... -- Nov 19, 2005
...common form of kidney cancer and the tenth most common cancer in the ... for patients with metastatic RCC include cytokines such as interferon-alpha, which has ... Medical News Today (press release),

InterMune Announces Presentations at the 56th Annual Meeting of ... -- Nov 8, 2005
Infergen® is the only interferon alpha with data in its label regarding use in ... the GRACES Trial, a Phase III study of interferon gamma-1b in ovarian cancer. ... Yahoo! News (press release)

Recently Discovered Genetic Patterns May Predict Lupus Activity -- Nov 13, 2005
Further organization of these transcripts revealed two key groups: genes induced by interferon-alpha, which is a natural cancer and infection fighter; and a ... Newswise (press release)

Helix Biopharma Corp. Announces Fiscal 2005 Results -- Nov 1, 2005
...the Phase II clinical study of the Company’s Topical Interferon Alpha-2b, research expenditures relating to the Company’s novel anti-cancer therapeutic, L ... PharmaLive.com (press release),

Roche Announces Expansion of First Major Study to Examine Efficacy ... -- Nov 3, 2005
...compensated liver disease and have not previously been treated with interferon alpha. ... diagnostics, the leading supplier of pharmaceuticals for cancer, as well ... PR Newswire (press release),

MethylGene Announces Third Quarter 2005 Results -- Nov 1, 2005
...disclosed. - Enrolment continues in the Phase II MG98 combination trial with interferon alpha for kidney cancer. Completed enrolment ... Business Wire (press release),

DOS47 scientific paper published in the Journal of Experimental ... -- Oct 25, 2005
...prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and ... PharmaLive.com (press release),

Mesothelioma Treatment 101 -- Oct 25, 2005
...to the patient (while it may benefit patients with bladder cancer). ... Nonetheless, other trials involving interferon alpha have proved more encouraging with 20 ... juiceenewsdaily,

Medarex Announces 2005 Third Quarter Financial Results -- Nov 4, 2005
1103), a fully human antibody targeting interferon-alpha in development ... life-threatening and debilitating diseases, including cancer, inflammation, autoimmune ... PR Newswire (press release),

DOS47 Scientific Paper Published in the Journal of Experimental ... -- Oct 25, 2005
...prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its Topical Interferon Alpha-2b and ... PharmaLive.com (press release),

Intralesional Bacille Calmette-Guerin Injection Effective for ... -- Oct 24, 2005
...and Director of Translational Tumor Immunology, John Wayne Cancer Institute, Santa ... ablation in 19% and after conversion to intralesional interferon alpha in 4 ... DG News

MedImmune Reports 2005 Third Quarter and Nine-Month Financial ... -- Oct 20, 2005
...pandemic influenza vaccines * IND submitted for antibody targeting interferon-alpha as a ... is focused on the areas of infectious disease, cancer and inflammatory ... PR Newswire (press release),

More information on Interferon alpha from the National Cancer Institute

Biological therapy is a type of treatment that works with your immune system. It can help fight cancer or help control side effects (how your body reacts to the drugs you are taking) from other cancer treatments like chemotherapy.

What is the difference between biological therapy and chemotherapy?

Biological therapy and chemotherapy are both treatments that fight cancer. While they may seem alike, they work in different ways. Biological therapy helps your immune system fight cancer. Chemotherapy attacks the cancer cells directly.

How does biological therapy fight cancer?

Doctors are not sure how biological therapy helps your immune system fight cancer. But they think it may:

Stop or slow the growth of cancer cells.
Make it easier for your immune system to destroy, or get rid of, cancer cells.
Keep cancer from spreading to other parts of your body.